Amgen’s Krystexxa reduces blood pressure in uncontrolled gout patients in MIRROR trial
Amgen has released updated findings from the Phase 4 MIRROR trial, which revealed that Krystexxa (pegloticase) could reduce blood pressure among adults dealing with uncontrolled gout, which is